Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks

JAIDS Journal of Acquired Immune Deficiency Syndromes 2026 Open access

Read full text
Authors: Laurie A. VanderVeen, Lisa Selzer, Silvia Chang, Jiani Li, Tracy L. Diamond, Ernest Asante-Appiah, Cyril Llamoso, M. Rhee, Christian Callebaut
DOI: 10.1097/qai.0000000000003873
Cited by: 2
References: 24

Abstract

BACKGROUND: Islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir (LEN), a capsid inhibitor, have pharmacokinetic profiles supporting once-weekly (QW) oral dosing. In a phase 2 study, QW ISL + LEN maintained a high rate (94.2%) of viral suppression (VS; HIV-1 RNA

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV Research and Treatment Virus-based gene therapy research

Publication details

Journal / source
JAIDS Journal of Acquired Immune Deficiency Syndromes
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
101
Issue
8
Pages
926–931
Publication date
26 March 2026
Language
EN